Cogent Biosciences, Inc. Cash and Restricted Cash
Cogent Biosciences, Inc. (COGT) had Cash and Restricted Cash of $181.59 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $181.59M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $241.62M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $312.43M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125.63M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $181.59M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $241.62M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $312.43M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $125.63M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $127.60M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $126.00M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $98.17M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $97.05M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $88.22M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $215.80M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $53.23M 10-K · filed 2026-02-17 |
| 2023-09-30 | $86.81M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $214.32M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $161.95M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $141.14M 10-K · filed 2026-02-17 |
| 2022-09-30 | $141.82M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $326.82M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $192.30M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $220.94M 10-K · filed 2025-02-25 |
| 2021-09-30 | $204.14M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $219.36M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $231.99M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $243.44M 10-K · filed 2024-02-26 |
| 2020-09-30 | $130.68M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $22.60M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $30.86M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $38.68M 10-K · filed 2022-03-15 |
| 2019-09-30 | $47.14M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $57.12M 10-Q · filed 2020-08-11 |
| 2019-03-31 | $60.37M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $56.93M 10-K · filed 2021-03-16 |
| 2018-09-30 | $50.55M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $48.04M 10-Q · filed 2019-08-12 |
| 2018-03-31 | $27.01M 10-Q · filed 2019-05-13 |
| 2017-12-31 | $29.60M 10-K · filed 2020-03-26 |
| 2017-09-30 | $31.95M 10-Q · filed 2018-11-13 |
| 2017-06-30 | $32.51M 10-Q · filed 2018-08-13 |
| 2017-03-31 | $34.49M 10-Q · filed 2018-05-14 |
| 2016-12-31 | $42.58M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |